Good Manufacturing Practice (GMP)

Good manufacturing practice is a body of legally enforceable requirements covering how a medicine is produced rather than whether it works. It reaches facility design and air classification, equipment qualification, process validation, approved procedures, in-process controls, release testing against a specification, and investigation of deviations. Sterile manufacture is governed in Europe by an annex revised in 2022 to require a formal contamination control strategy. The word current is doing work: the standard rises as the industry's capability does.

Compliance is established by inspection, not assertion. Inspectors visit named, registered sites and issue written observations; unresolved problems escalate to warning letters and, for imported product, to alerts blocking entry at the border. The scope is the operation, not the molecule, and it does not transfer: an active ingredient made under a compliant system and then filled into vials in an unqualified room does not yield a compliant product.

The practical difference from a research-grade peptide that happens to test well is reproducibility with evidence. A single excellent analytical result tells you about one sample. A functioning quality system tells you the next lot will be made the same way, tested by qualified staff on qualified instruments against a fixed specification, and that a failure would be recorded and investigated rather than quietly reblended.

Two misuses are worth naming. The phrase appears as marketing on research-chemical listings with no inspection, no registered site and no authority behind it, when the status is one a regulator confers on a facility rather than one a seller assigns itself. And compliance implies nothing about efficacy or approval: a compound with no clinical evidence and no marketing authorisation, made impeccably, is still an unapproved compound.